

Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
November 6, 2025

**Notice Regarding Revisions to Consolidated Performance Forecast
(Prepared Based on Japan's Generally Accepted Accounting Principles (GAAP))**

Due to recent performance trends and other factors, the Company has revised its consolidated performance forecast for fiscal 2025, which was announced on May 15, 2025. The revised forecast is as follows.

1. Revised Consolidated Performance Forecast for Fiscal 2025 (April 1, 2025–March 31, 2026)

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of the parent	Earnings per share of common stock
Previous forecast (A)	3,107,000	37,100	39,700	25,000	¥137.52
Revised forecast (B)	3,107,000	37,100	39,700	36,000	¥198.07
Change (B-A)	—	—	—	11,000	
Percentage change (%)	—	—	—	44.0	
(Ref.) Results from the previous fiscal year (fiscal 2024)	2,961,051	38,080	40,485	27,389	¥147.54

2. Reasons for Revisions

Extraordinary profit is expected to be posted stemming from the sale of investment securities, based on efforts to reduce cross-shareholdings. Accordingly, profit attributable to owners of the parent in the consolidated performance forecast for fiscal 2025 is expected to far exceed the initial forecast.

Note: The above forecast was prepared on the basis of available information at the time of the release of this notice. Actual performance may differ substantially from these forecasts due to various factors.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, and regenerative medicine-related business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.9 trillion for the fiscal year ended March 31, 2025. For more information, please see: <https://www.alfresa.com/eng/>